Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
藤野 隼輔; 橋本 和幸; 佐伯 秀也*; 河内 幸正*; 川端 方子*; 千葉 悠介
no journal, ,
Lu-177は神経内分泌腫瘍の治療薬として、ルタテラが国内承認されており、さらなる治療薬開発が期待されている核種の1つである。しかし、Lu-177は海外からの輸入に依存しており、輸送トラブル等により国内流通及び薬剤開発等に影響を及ぼすことが懸念される。そのため、原子力機構でLu-177の一部を国内で製造可能かどうかを確認するため、JRR-3を用いたLu-177の生成量評価を実施した。
渡辺 杏*; 藤野 隼輔; 高木 直行*
no journal, ,
Targeted Radionuclide Therapy using Lu-177 is mainly used to treat prostate cancer and is attracting attention as a new treatment method that can also treat transition cancer cells. Although Lu-177 is being produced by research reactor around the world, Lu-177 production has not yet taken place in Japan. There are two ways to produce Lu-177 in reactors: direct production by the Lu-176(n,
) reaction and indirect production by the Yb-176(n, 
) reaction. The former method of enriched Lu-176 yields a large amount of Lu-177, but the specific activity is as small as about 0.5 TBq/mg-Lu at the neutron flux level of commercial light water reactors. On the other hand, the indirect method using enriched Yb-176 yields less Lu-177 than direct production, but it has a high specific activity of about 4 TBq/mg-Lu and enables the production of no carrier added (nca) Lu-177 without the waste problem of Lu-177m (half-life: 160 days). The objective of this study is to produce Lu-177 using a nuclear reactor, with the goal of supplying 15,000 castration-resistant prostate cancer patients in Japan. To achieve mass production in commercial light water reactors in the future, we first conducted experiments and analysis on JRR-3.
藤野 隼輔; 千葉 悠介
no journal, ,
In the past, JAEA used to manufacture radioisotopes for medicine and industry, but our radioisotope manufacturing projects has been downsized considering the decrease in the number of operating research reactors and the shutdown of reactors. Due to the reduction of radioisotope production, most of the radioisotopes used in Japan are dependent on imports from overseas, and there is concern that supply disruptions caused by external factors may hinder the use of radioisotopes. In particular, the production and stable supply of medical radioisotopes in Japan has become an issue due to the recent international situation and transportation troubles. Therefore, the Atomic Energy Commission formulated the "Action Plan for the Production and Utilization of Radioisotopes for Medical Use" on May 31, 2022. One of the goals of this action plan is to produce and supply approximately 30% of the domestic demand for Mo-99 using JRR-3. In addition to the above, the production for sealed radioactive sources in medical and industrial use has been restarted since the resumption of JRR-3 operation at 2021. And the production of Lu-177 has been developed in progress.